Vivakor, Inc. quarterly report, Q3 FY2009

Vivakor, Inc. 10-Q Summary: Quarter Ended September 30, 2009

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Vivakor, Inc., a Nevada corporation and smaller reporting company, for the period ended September 30, 2009. Vivakor is a trans-disciplinary biomedical company focused on the discovery, development, and commercialization of medical devices, pharmaceuticals, and contract research services. The company operates through four primary divisions: Molecular Medicine, Electro-Optics, Biological Handling, and Natural/Formulary Products. As of the reporting date, the company had 62,245,802 shares of common stock outstanding.

Key Financial Metrics

MetricThree Months Ended Sep 30, 2009Nine Months Ended Sep 30, 2009Balance Sheet (Sep 30, 2009)
Total Revenues$48,360$143,347-
Net Loss (Attributable to Vivakor)$(591,251)$(1,396,986)-
Operating Loss$(636,182)$(1,431,181)-
Cash and Cash Equivalents--$69,299
Total Current Liabilities--$1,914,799
Notes Payable--$500,000
Accrued Wages and Benefits--$731,307
Retained Deficit--$(2,445,946)

Revenue Composition (9 Months 2009): Grants ($112,912), Product Sales ($30,435), Research Services ($0).
Cash Flow (9 Months 2009): Net cash used in operating activities was $(147,340). Net cash provided by financing activities was $70,970, primarily from stock sales and notes receivable.

Material Changes vs. Prior Period

  • Revenue Shift: Research services revenue dropped to zero in 2009 compared to $49,700 in the prior quarter. This was offset by new product sales ($10,148) and grant revenue ($38,212) in the current quarter, which were non-existent in the prior year.
  • Expense Increase: Operating expenses surged to $684,542 (3 months) and $1,574,528 (9 months) compared to $250,861 and $483,574 in the prior year periods. This increase is driven by higher R&D costs (including patent amortization of ~$185k/quarter), increased G&A due to executive compensation, and new sales/marketing costs.
  • One-Time Charges: The company expensed $111,316 in abandoned offering costs related to a terminated capital formation activity in the first quarter of 2009.
  • Debt Reduction: The Note Payable balance decreased from $1,481,648 (Dec 31, 2008) to $500,000 (Sep 30, 2009) primarily through debt-for-equity swaps with a related party.

Outlook, Risks, and Management Commentary

Going Concern: Management and auditors have expressed substantial doubt regarding the company's ability to continue as a going concern. The company does not have sufficient cash to fund operations for the next 12 months and relies on future financing, grants, or strategic partnerships.

Liquidity and Debt: The company is in default on a $500,000 note payable related to the HealthAmerica acquisition, failing to make required monthly payments. However, the note holder (a related party) has not taken enforcement action. The company also holds $1,341,845 in notes receivable from recent stock sales, with no assurance of collection.

Capital Formation: A new S-1 registration was declared effective in August 2009. As of September 30, the company raised $149,575 in cash and issued shares for services and debt reduction. A previous offering in early 2009 was terminated after failing to receive payments on subscription agreements.

Operations: The company reduced its workforce, laying off all employees except the Chairman, CEO, and CFO in July 2009 due to funding constraints. Significant portions of executive salaries remain accrued.

Investor Verification Checklist

  • Cash Runway: Verify current cash balance ($69,299) against monthly burn rate and accrued liabilities ($731k in wages) to assess immediate solvency risk.
  • Debt Default Status: Confirm the status of the $500,000 note payable default and whether the related-party note holder has agreed to further forbearance.
  • Notes Receivable Collection: Assess the likelihood of collecting the $1.34 million in notes receivable issued in exchange for stock, which matured in October 2009 and were extended.
  • Grant Repayment Triggers: Review the terms of the $157,099 grant payable, which requires repayment if an IPO is filed or the company moves out of Iowa.
  • Revenue Sustainability: Evaluate the sustainability of grant revenue ($112k) versus the lack of recurring commercial product sales.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.